-
Diagnostics World | The lab of W. Andy Tao, professor of biochemistry at Purdue University, is pioneering a way to assess drug response based on metabolizing proteins found in circulating extracellular vesicles (EVs), which could serve as a surrogate of their expression level in the liver and become therapeutic targets for some cancers.
May 15, 2024
-
Diagnostics World | A cancer researcher at Florida International University (FIU) has developed a functional precision medicine (FPM) approach to oncology treatment decision-making that combines genomic profiling with drug sensitivity testing on patient-derived tumor cells. Children with relapsed or refractory cancers are among the initial beneficiaries.
May 14, 2024
-
Diagnostics World | Every resource in healthcare is precious. The last few years have tested healthcare systems in almost every way, with significant impacts on their long-term financial health and, by extension, the quality of care they can provide. A 2023 report by the American Hospital Association estimates that overall hospital expenses rose by 17.5% between 2019 and 2022.
May 10, 2024
-
Diagnostics World | In oncology, it is well appreciated that time is life. Diagnostics are therefore valuable not just to determine the disease state of patients but how best to treat them, says Jane Li, senior director of oncology, pharma, and CRO partnerships related to clinical sequencing at Thermo Fisher Scientific.
May 7, 2024
-
Diagnostics World | A much-anticipated rule to regulate laboratory developed tests (LDTs) as medical devices has arrived, with significant implications for the diagnostic industry and patient care. Here’s a closer look at the historical context underlying the new rule, the debate leading up to this moment, recent updates, and the road ahead.
May 2, 2024
-
Diagnostics World | Significant evidence now exists implicating the Epstein-Barr virus (EBV) as a causal factor in the development of multiple sclerosis (MS), making treatment of the virus a priority. To that end, research scientists at Trinity College Dublin have developed a blood test to measure the immune response to EBV that could be used as an outcome measure in future clinical trials in people with established MS.
May 1, 2024